Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness - PubMed (original) (raw)
Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness
L Buø et al. Hum Pathol. 1995 Oct.
Abstract
The distributions of urokinase and tissue plasminogen activators (uPA, tPA), uPA receptor (uPAR), and plasminogen activator inhibitors (PAI-1, PAI-2) were studied immunohistochemically in two subsets of colorectal adenocarcinomas with low and high aggressiveness, respectively: nine Dukes' stage A tumors with additional other good prognostic markers and 13 Duke's stage C tumors with also other poor prognostic markers (referred to as Dukes' stage A and Dukes' stage C tumors). The results showed that these components of the tissue destructive plasminogen activation system were accumulated at the invading front of the tumors. Both tumor groups showed accumulations of uPA, uPAR, and PAI-1 at the tumor-host interface compared with the location within the tumor epithelium and the adjacent normal mucosa and muscularis propria (all P < .05). However, the uPA level at the tumor-host interface in the Dukes' stage C tumors was twice the level in the Dukes' stage A tumors (P < .05). The uPAR level was also significantly higher in the Dukes' stage C tumors (P < .05), whereas the PAI-1 level was not significantly higher. This may indicate that uPA in more aggressive tumors exceeds the inhibitory capacity represented by PAIs, resulting in enhanced tissue destructive potential that promotes tumor invasion. uPA and uPAR antigen levels and the uPA/PAI-1 ratio at the tumor-host interface appeared to be related to tumor aggressiveness in colorectal cancer.
Similar articles
- Plasminogen Activation System in Rectal Adenocarcinoma.
Razik E, Kobierzycki C, Grzegrzolka J, Podhorska-Okolow M, Drag-Zalesinska M, Zabel M, Dziegiel P. Razik E, et al. Anticancer Res. 2015 Nov;35(11):6009-15. Anticancer Res. 2015. PMID: 26504024 - Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J, Urano T, Konno H, Erhan Y, Tanaka T, Nishino N, Takada A, Nakamura S. Abe J, et al. Cancer. 1999 Dec 15;86(12):2602-11. doi: 10.1002/(sici)1097-0142(19991215)86:12<2602::aid-cncr4>3.0.co;2-s. Cancer. 1999. PMID: 10594855 - Plasminogen activator system in oral squamous cell carcinoma.
Baker EA, Leaper DJ, Hayter JP, Dickenson AJ. Baker EA, et al. Br J Oral Maxillofac Surg. 2007 Dec;45(8):623-7. doi: 10.1016/j.bjoms.2007.04.021. Epub 2007 Jun 21. Br J Oral Maxillofac Surg. 2007. PMID: 17590247 - The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D, Chen J, Aghmesheh M, Vine KL, Becker TM, Carolan MG, Ranson M. Brungs D, et al. Oncotarget. 2017 Apr 4;8(14):23099-23109. doi: 10.18632/oncotarget.15485. Oncotarget. 2017. PMID: 28416743 Free PMC article. Review. - [The urokinase-type plasminogen activator system and its role in tumor progression].
Kugaevskaya EV, Gureeva TA, Timoshenko OS, Solovyeva NI. Kugaevskaya EV, et al. Biomed Khim. 2018 Nov;64(6):472-486. doi: 10.18097/PBMC20186406472. Biomed Khim. 2018. PMID: 30632975 Review. Russian.
Cited by
- The Urokinase Plasminogen Activation System in Pancreatic Cancer: Prospective Diagnostic and Therapeutic Targets.
Kumar AA, Buckley BJ, Ranson M. Kumar AA, et al. Biomolecules. 2022 Jan 18;12(2):152. doi: 10.3390/biom12020152. Biomolecules. 2022. PMID: 35204653 Free PMC article. Review. - The Soluble Urokinase-Type Plasminogen Activator Receptor as a Biomarker for Survival and Early Treatment Effect in Metastatic Colorectal Cancer.
Blomberg K, Hansen TF, Brasen CL, Madsen JB, Jensen LH, Thomsen CB. Blomberg K, et al. Cancers (Basel). 2021 Oct 12;13(20):5100. doi: 10.3390/cancers13205100. Cancers (Basel). 2021. PMID: 34680247 Free PMC article. - S100A10, a novel biomarker in pancreatic ductal adenocarcinoma.
Bydoun M, Sterea A, Liptay H, Uzans A, Huang WY, Rodrigues GJ, Weaver ICG, Gu H, Waisman DM. Bydoun M, et al. Mol Oncol. 2018 Nov;12(11):1895-1916. doi: 10.1002/1878-0261.12356. Epub 2018 Sep 21. Mol Oncol. 2018. PMID: 30009399 Free PMC article. - Peritoneum as the sole distant metastatic site of lung adenosquamous cell carcinoma: a case report.
Yang P, Li WL, Zhou JX, Yang YB, Jin XX. Yang P, et al. J Med Case Rep. 2017 Sep 27;11(1):274. doi: 10.1186/s13256-017-1431-z. J Med Case Rep. 2017. PMID: 28950878 Free PMC article. - Association between KRAS mutation and lung metastasis in advanced colorectal cancer.
Pereira AA, Rego JF, Morris V, Overman MJ, Eng C, Garrett CR, Boutin AT, Ferrarotto R, Lee M, Jiang ZQ, Hoff PM, Vauthey JN, Vilar E, Maru D, Kopetz S. Pereira AA, et al. Br J Cancer. 2015 Feb 3;112(3):424-8. doi: 10.1038/bjc.2014.619. Epub 2014 Dec 23. Br J Cancer. 2015. PMID: 25535726 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous